PathNet is a collective of world-class pathologists working together to improve patient care.
PathNet is committed to leveraging the latest and best technology to drive pathology into the digital age.
PathNet was founded by pathologists for pathologists with the goal to move pathology forward. By leveraging digital technologies, PathNet lowers costs without compromising on quality.
The benefits of practicing digital pathology with PathNet reach beyond the pathologist and into the laboratory workflow and patient results. Efficiencies created in the laboratory setting bring faster tissue processing and improved turnaround times. On the patient level, digital pathology services bring detailed results that allow for personalized care and treatment.
Committed to leveraging the latest and best technology, PathNet believes that by pairing technology with forward-thinking physicians, we will provide superior patient care. We welcome pathologists and patient-facing physicians alike who recognize that there is a better way.
Meet Our Pathologists
Dr. Matthew O. Leavitt
Dr. Leavitt did his medical training at Dartmouth Medical School, and then completed a pathology residency and two fellowships at Stanford University Hospital. He served as department chair in an urban medical center, where he oversaw lab diagnostics for patients referred from some of the most geographically remote communities in the United States. In that role, he became passionate about utilizing digital pathology to improve the quality of cancer care afforded patients in underserved areas. He currently works as CEO of PathNet labs, a network of digital pathology practices, with partners across the U.S.
Dr. Kirk J. Wojno
Dr. Wojno is the founder and a co-owner of MDpath. He has served on scientific advisory boards and as a consultant to many of the top molecular diagnostic companies. He continues to educate the next generation of physicians and scientists and is a highly sought-after lecturer. He is also an active member of the College of American Pathologists as well as numerous other societies where he advocates for appropriate and ethical use of, as well as fair access to, advanced molecular laboratory testing. He truly strives to use his gifts to make a difference in patients’ lives.
Dr. Adam J. Cole
Dr. Adam Cole graduated with honors from the University of Arkansas with a bachelor’s degree in microbiology and earned his master’s degree in health science from Duke University. He concluded his medical training with a residency in pathology at the University of Arkansas for Medical Sciences.
Adam is board certified in both Anatomic and Clinical Pathology with a Genitourinary and Molecular Pathology focus. He is a Key Opinion Leader and national speaker for several Genomic companies.
In addition to his medical education, he also serves as a Lt Col in the United States Air Force (Reserve) as a command flight surgeon.
Dr. Todd Randolph
Dr. Randolph lives near Park City, Utah, and is board certified in anatomic pathology and cytopathology with over 20 years of experience, working within and managing laboratories for some of the most well-recognized hospital systems and commercial labs in the United States. He is also experienced in clinical research and the validation of new diagnostic medical technologies. He has years of experience bridging the gap between clinical lab applications and the achievement of commercial objectives.
Dr. Hillel Kahane
Dr. Kahane lives on Long Island, New York, & is a board-certified urologic pathologist, with over 28 years of experience. He has diagnosed well over 1,000,000 prostate needle core biopsies, for over 6,000 urologists and radiation oncologists nationwide in two of the largest prostate biopsy laboratories in the United States. Dr. Kahane has the unique distinction of having worked with and published with both Jonathan I. Epstein, M.D. and David G. Bostwick, M.D.
Dr. Jared Szymanski
Dr. Jared Szymanski has over 13 years of experience as a general pathologist. He graduated from the Arizona College of Osteopathic Medicine in 2003, completing his residency and fellowship at Texas A&M. He is board certified in anatomic and clinical pathology as well as cytopathology. He co-founded what would become the laboratory technology company Lumea and in 2020 left his hospital practice at Utah Valley Hospital to start ConnectPathology with partner Dr. Anthony Perry, where they are building a digital pathology practice applying technology to improve the laboratory process from the patient bedside through diagnosis and ancillary testing.
Dr. Anthony Perry
Dr. Anthony Perry pursued his education at Mayo Clinic, Texas A&M, and Tulane University, obtaining an MD and Ph.D. He completed his residency at Dignity Health Global Education and his fellowship at Harvard Medical School. Dr. Perry worked as a Principal Scientist at Spirus Laboratories and the Canadian Food Inspection Agency during his medical education. Before co-founding ConnectPathology, he worked at Intermountain Health Care as a Pathologist for 7 years.
Dr. Nicole A Massoll
Dr. Massoll received her medical degree and completed her Anatomic and Clinical Pathology residency at the University of Arkansas for Medical Sciences and went on to receive her Cytopathology training with genitourinary pathologist Dr. William Murphy. Dr. Massoll has over 17 years of experience in both private and academic settings. She became one of the first cytopathologists to learn Ultrasound-guided Fine Needle Aspiration procedures and has performed thousands of thyroid US guided FNAs.
Dr. Matthew R. Lindberg
Dr. Lindberg is a graduate of the University of Arkansas for Medical Sciences (UAMS) in Little Rock. He completed his Pathology residency training at UAMS along with a Fellowship in Surgical Pathology, where he received focused training in gastrointestinal, genitourinary, and soft tissue pathology. Dr. Lindberg has over seven years of experience in both private and academic settings and also holds a current faculty appointment at UAMS.
Ready to get started?
Join our family by becoming a PathNet pathologist or by sending biopsies to one of our groups for diagnostic analysis.